Arcoma (ARCOMA.ST) Stock Analysis & AI Equity Report

Medical - Devices SEK Explore free reports

Arcoma (ARCOMA.ST) overview

Arcoma (ARCOMA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Arcoma reported revenue of SEK 131m and operating profit of SEK 8.7m; the year-end share price was 7.34 SEK and market capitalisation was SEK 105m. Arcoma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arcoma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueSEK 74.7mFY 2025
Share price7.34 SEKFY 2025 year end
RevenueSEK 131mFY 2025
Operating profitSEK 8.7mFY 2025
Net earningsSEK 5.0mFY 2025
Market capitalisationSEK 105mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About Arcoma

Arcoma AB develops, produces and supplies complete digital radiography and radiology solutions, including X-ray systems, detectors and accessories for hospitals and clinics. The company manufactures in Sweden and sells through OEM partners and distributors internationally. Its products are used across general radiology and specialized applications, with emphasis on workflow, ergonomics and patient comfort.

Generate the Arcoma report

Arcoma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Arcoma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Arcoma

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.